{"transactions":[{"id":3585618,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-08T22:08:51.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":274430,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-060962","document":"wk-form4_1788905328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026060962/wk-form4_1788905328.xml","form_type":"4"}},{"id":3585617,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-09-08T22:08:51.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":16.4566,"value":41141.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-060962","document":"wk-form4_1788905328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026060962/wk-form4_1788905328.xml","form_type":"4"}},{"id":3585616,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-09-08T22:08:51.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.01,"value":2525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0001628280-26-060962","document":"wk-form4_1788905328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026060962/wk-form4_1788905328.xml","form_type":"4"}},{"id":698968,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-03T22:14:32.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":276930,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-052031","document":"wk-form4_1785795270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026052031/wk-form4_1785795270.xml","form_type":"4"}},{"id":698967,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-08-03T22:14:32.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":16.0116,"value":40029.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-052031","document":"wk-form4_1785795270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026052031/wk-form4_1785795270.xml","form_type":"4"}},{"id":698966,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-08-03T22:14:32.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.01,"value":2525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0001628280-26-052031","document":"wk-form4_1785795270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026052031/wk-form4_1785795270.xml","form_type":"4"}},{"id":711232,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":25,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":33257,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":25},"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711231,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":1015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":33282,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":1015},"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711230,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":25,"price":16,"value":400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":135202,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711229,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":25,"price":1.01,"value":25.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":135227,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711228,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":1015,"price":16,"value":16240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":135202,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711227,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":1015,"price":1.01,"value":1025.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":136217,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":712734,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-08T22:49:19.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":279430,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-047710","document":"wk-form4_1783550956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026047710/wk-form4_1783550956.xml","form_type":"4"}},{"id":712733,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-08T22:49:19.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-047710","document":"wk-form4_1783550956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026047710/wk-form4_1783550956.xml","form_type":"4"}},{"id":712732,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-08T22:49:19.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.01,"value":2525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0001628280-26-047710","document":"wk-form4_1783550956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026047710/wk-form4_1783550956.xml","form_type":"4"}},{"id":718300,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":4183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock options are fully vested and exercisable."}],"balance_after":34297,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":4183},"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718299,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T21:47:14.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":28826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock options are fully vested and exercisable."}],"balance_after":38480,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":28826},"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718298,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":2501,"price":16.2369,"value":40608.4869,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":135202,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718297,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":5852,"price":15.6667,"value":91681.5284,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15  to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":137703,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718296,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":4183,"price":1.01,"value":4224.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":143555,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718295,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":28826,"price":16.0372,"value":462288.3272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":139372,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718294,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":28826,"price":1.01,"value":29114.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":168198,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":721609,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T23:04:56.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":10833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":238334,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":10833},"source":{"system":"sec-edgar","filing":"0001628280-26-046654","document":"wk-form4_1782947093.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000162828026046654/wk-form4_1782947093.xml","form_type":"4"}},{"id":721608,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:56.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":10833,"price":16.0242,"value":173590.1586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c)."}],"balance_after":8961,"source":{"system":"sec-edgar","filing":"0001628280-26-046654","document":"wk-form4_1782947093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000162828026046654/wk-form4_1782947093.xml","form_type":"4"}},{"id":721607,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:56.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":10833,"price":4.5,"value":48748.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19794,"source":{"system":"sec-edgar","filing":"0001628280-26-046654","document":"wk-form4_1782947093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000162828026046654/wk-form4_1782947093.xml","form_type":"4"}},{"id":721385,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":118417,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721384,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":281930,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721383,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":16.008,"value":160080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c)."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721382,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.26,"value":3150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":27217,"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721381,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":1.01,"value":7575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":24717,"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":725615,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:46:26.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045845","document":"wk-form4_1782510384.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045845/wk-form4_1782510384.xml","form_type":"4"}},{"id":725616,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35191,"kind":"person","name":"Lyons-Williams Lori","position":1,"cik":"0001693564","reported_name":"Lyons-Williams Lori","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:45:27.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045843","document":"wk-form4_1782510325.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045843/wk-form4_1782510325.xml","form_type":"4"}},{"id":725614,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:44:57.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045841","document":"wk-form4_1782510295.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045841/wk-form4_1782510295.xml","form_type":"4"}},{"id":725613,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:44:27.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045839","document":"wk-form4_1782510265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045839/wk-form4_1782510265.xml","form_type":"4"}},{"id":725612,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:43:48.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045837","document":"wk-form4_1782510226.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045837/wk-form4_1782510226.xml","form_type":"4"}},{"id":725610,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35185,"kind":"person","name":"Brady Todd R.","position":1,"cik":"0001767644","reported_name":"Brady Todd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:43:11.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045835","document":"wk-form4_1782510189.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045835/wk-form4_1782510189.xml","form_type":"4"}},{"id":725611,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:42:22.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045833","document":"wk-form4_1782510140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045833/wk-form4_1782510140.xml","form_type":"4"}},{"id":757199,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-06-01T22:08:39.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":13.1564,"value":54862.188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.995  to $13.360, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":139372,"source":{"system":"sec-edgar","filing":"0001628280-26-039641","document":"wk-form4_1780351717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026039641/wk-form4_1780351717.xml","form_type":"4"}},{"id":795814,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-05-01T21:42:37.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":300,"price":13.84,"value":4152.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $13.86, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":143542,"source":{"system":"sec-edgar","filing":"0001628280-26-029435","document":"wk-form4_1777671753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026029435/wk-form4_1777671753.xml","form_type":"4"}},{"id":795813,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-05-01T21:42:37.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":3870,"price":13.06,"value":50542.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69  to $13.57, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":143842,"source":{"system":"sec-edgar","filing":"0001628280-26-029435","document":"wk-form4_1777671753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026029435/wk-form4_1777671753.xml","form_type":"4"}},{"id":814528,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-04-06T21:43:32.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":13.4326,"value":56013.942,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":147712,"source":{"system":"sec-edgar","filing":"0001628280-26-023949","document":"wk-form4_1775511809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026023949/wk-form4_1775511809.xml","form_type":"4"}},{"id":874471,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-02T23:30:02.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":15.0084,"value":62585.028,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":151882,"source":{"system":"sec-edgar","filing":"0001437749-26-006422","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926006422/rdgdoc.xml","form_type":"4"}},{"id":874834,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-02T23:28:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":3611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":249167,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":3611},"source":{"system":"sec-edgar","filing":"0001437749-26-006421","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926006421/rdgdoc.xml","form_type":"4"}},{"id":874833,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-03-02T23:28:58.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3611,"price":15.0153,"value":54220.2483,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-26-006421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926006421/rdgdoc.xml","form_type":"4"}},{"id":874832,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-03-02T23:28:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":3611,"price":4.5,"value":16249.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":3611,"source":{"system":"sec-edgar","filing":"0001437749-26-006421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926006421/rdgdoc.xml","form_type":"4"}},{"id":879853,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":2700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":120917,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":2700},"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879852,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":123617,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":4400},"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879851,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":2700,"price":16.0155,"value":43241.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879850,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":2700,"price":1.26,"value":3402.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":17654,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879849,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":4400,"price":16.0195,"value":70485.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879848,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":4400,"price":1.26,"value":5544.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19354,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879847,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":3824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":67306,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":3824},"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879846,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":4300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":71130,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":4300},"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879845,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":3824,"price":16.0115,"value":61227.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879844,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":3824,"price":1.01,"value":3862.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":159876,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879843,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":4300,"price":16.0316,"value":68935.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879842,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":4300,"price":1.01,"value":4343.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":160352,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":890846,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T21:05:35.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":75430,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001437749-26-004912","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004912/rdgdoc.xml","form_type":"4"}},{"id":890845,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-20T21:05:35.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":100,"price":16,"value":1600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-004912","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004912/rdgdoc.xml","form_type":"4"}},{"id":890844,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-20T21:05:35.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":1.01,"value":101.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156152,"source":{"system":"sec-edgar","filing":"0001437749-26-004912","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004912/rdgdoc.xml","form_type":"4"}},{"id":905369,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-13T21:27:47.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options are fully vested and exercisable."}],"balance_after":128017,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001437749-26-004126","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926004126/rdgdoc.xml","form_type":"4"}},{"id":905368,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:27:47.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":400,"price":16,"value":6400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001437749-26-004126","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926004126/rdgdoc.xml","form_type":"4"}},{"id":905367,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:27:47.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":1.26,"value":504.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,246 shares purchased through Issuer's Employee Stock Purchase Plan on November 15, 2024 and 2,096 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025."}],"balance_after":15354,"source":{"system":"sec-edgar","filing":"0001437749-26-004126","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926004126/rdgdoc.xml","form_type":"4"}},{"id":905366,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-13T21:26:06.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":75530,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001437749-26-004122","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004122/rdgdoc.xml","form_type":"4"}},{"id":905365,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:26:06.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":400,"price":16,"value":6400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-004122","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004122/rdgdoc.xml","form_type":"4"}},{"id":905364,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:26:06.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":1.01,"value":404.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156452,"source":{"system":"sec-edgar","filing":"0001437749-26-004122","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004122/rdgdoc.xml","form_type":"4"}},{"id":917845,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-05T21:24:59.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":1170,"price":15.2451,"value":17836.767,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $15.45, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-003212","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926003212/rdgdoc.xml","form_type":"4"}},{"id":917844,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-05T21:24:59.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":14.8229,"value":44468.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $15.08, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":157222,"source":{"system":"sec-edgar","filing":"0001437749-26-003212","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926003212/rdgdoc.xml","form_type":"4"}},{"id":927103,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":68399,"kind":"person","name":"Healy John Stephen","position":1,"cik":"0001908071","reported_name":"Healy John Stephen","relationship":{"officer":true,"officer_title":"General Counsel and Corp Sec"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:59:54.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":206411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":206411,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":206411},"source":{"system":"sec-edgar","filing":"0001437749-26-002579","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774926002579/rdgdoc.xml","form_type":"4"}},{"id":927102,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":68398,"kind":"person","name":"Slover Peter T","position":1,"cik":"0001468012","reported_name":"Slover Peter T","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:57:46.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":192000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":192000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":192000},"source":{"system":"sec-edgar","filing":"0001437749-26-002578","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774926002578/rdgdoc.xml","form_type":"4"}},{"id":927108,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:56:17.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":445000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":445000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":445000},"source":{"system":"sec-edgar","filing":"0001437749-26-002577","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926002577/rdgdoc.xml","form_type":"4"}},{"id":927107,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:54:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's spouse's continuous service."}],"balance_after":6500,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001437749-26-002576","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926002576/rdgdoc.xml","form_type":"4"}},{"id":927106,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:54:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"). The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":160000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001437749-26-002576","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926002576/rdgdoc.xml","form_type":"4"}},{"id":927267,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-30","kind":"grant","planned":true,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":160000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927266,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":false,"shares":3611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":252778,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":3611},"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927265,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"sale","planned":true,"acquired":false,"shares":811,"price":14.4848,"value":11747.1728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927264,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"sale","planned":true,"acquired":false,"shares":2800,"price":14.0861,"value":39441.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":811,"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927263,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":true,"shares":3611,"price":4.5,"value":16249.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":3611,"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":947035,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-01-06T21:16:27.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":500,"price":11.1298,"value":5564.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.34, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":160222,"source":{"system":"sec-edgar","filing":"0001437749-26-000616","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926000616/rdgdoc.xml","form_type":"4"}},{"id":947034,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-01-06T21:16:27.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":3670,"price":10.3483,"value":37978.261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.000 to $10.955, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":160722,"source":{"system":"sec-edgar","filing":"0001437749-26-000616","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926000616/rdgdoc.xml","form_type":"4"}},{"id":957372,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-30T21:12:15.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":3611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":256389,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":3611},"source":{"system":"sec-edgar","filing":"0001437749-25-038938","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925038938/rdgdoc.xml","form_type":"4"}},{"id":957371,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2025-12-30T21:12:15.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":3611,"price":12.0627,"value":43558.4097,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-25-038938","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925038938/rdgdoc.xml","form_type":"4"}},{"id":957370,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2025-12-30T21:12:15.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":3611,"price":4.5,"value":16249.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":3611,"source":{"system":"sec-edgar","filing":"0001437749-25-038938","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925038938/rdgdoc.xml","form_type":"4"}},{"id":957255,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-30T21:10:34.000Z","date":"2025-12-23","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":12.2324,"value":51009.108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.38, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":164392,"source":{"system":"sec-edgar","filing":"0001437749-25-038936","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774925038936/rdgdoc.xml","form_type":"4"}},{"id":1101139,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:50:00.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021373","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021373/rdgdoc.xml","form_type":"4"}},{"id":1101140,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:47:53.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021372","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021372/rdgdoc.xml","form_type":"4"}},{"id":1101138,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35185,"kind":"person","name":"Brady Todd R.","position":1,"cik":"0001767644","reported_name":"Brady Todd R.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:46:34.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021371","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021371/rdgdoc.xml","form_type":"4"}},{"id":1101137,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:44:32.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021369","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021369/rdgdoc.xml","form_type":"4"}},{"id":1101136,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35191,"kind":"person","name":"Lyons-Williams Lori","position":1,"cik":"0001693564","reported_name":"Lyons-Williams Lori","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:43:18.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021367","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021367/rdgdoc.xml","form_type":"4"}},{"id":1101135,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35189,"kind":"person","name":"Ware Olivia C","position":1,"cik":"0001663771","reported_name":"Ware Olivia C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:41:51.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021366","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021366/rdgdoc.xml","form_type":"4"}},{"id":1101134,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:39:45.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021365","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021365/rdgdoc.xml","form_type":"4"}},{"id":1164998,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-28T20:21:48.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service."}],"balance_after":26000,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001437749-25-013340","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925013340/rdgdoc.xml","form_type":"4"}},{"id":1164997,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-28T20:21:48.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted outside of the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":260000,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001437749-25-013340","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925013340/rdgdoc.xml","form_type":"4"}},{"id":1203998,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-03-17T20:12:41.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on March 14, 2026, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":29500,"derivative":{"exercise_price":6.67,"expiration_date":"2035-03-13","underlying":"Class A Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001437749-25-008003","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925008003/rdgdoc.xml","form_type":"4"}},{"id":1289681,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":68399,"kind":"person","name":"Healy John Stephen","position":1,"cik":"0001908071","reported_name":"Healy John Stephen","relationship":{"officer":true,"officer_title":"General Counsel and Corp Sec"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:41:28.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":63589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan.  25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":63589,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":63589},"source":{"system":"sec-edgar","filing":"0001437749-25-002436","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925002436/rdgdoc.xml","form_type":"4"}},{"id":1289680,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":68398,"kind":"person","name":"Slover Peter T","position":1,"cik":"0001468012","reported_name":"Slover Peter T","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:40:30.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026 and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":110000,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001437749-25-002435","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925002435/rdgdoc.xml","form_type":"4"}},{"id":1289685,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:38:59.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service."}],"balance_after":3700,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":3700},"source":{"system":"sec-edgar","filing":"0001437749-25-002431","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774925002431/rdgdoc.xml","form_type":"4"}},{"id":1289684,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:38:59.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"). 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":110000,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001437749-25-002431","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774925002431/rdgdoc.xml","form_type":"4"}},{"id":1289686,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:35:27.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":300000,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001437749-25-002424","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774925002424/rdgdoc.xml","form_type":"4"}},{"id":1289688,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":83737,"kind":"person","name":"Huhn Stephen L.","position":1,"cik":"0001863904","reported_name":"Huhn Stephen L.","relationship":{"officer":true,"officer_title":"CMO & Sr VP, Clinical Dev."}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T16:38:01.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":110000,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001437749-25-002429","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863904/000143774925002429/rdgdoc.xml","form_type":"4"}}],"next_cursor":"2025-01-31T16:38:01.000000Z,1289688"}